Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder

The α(2)-adrenergic receptor agonist guanfacine, in its extended-release formulation (GXR), is the most recent nonstimulant medication approved in several countries for the treatment of attention-deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive pharmacotherapy to stimulants in...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Raga, Jose, Knecht, Carlos, de Alvaro, Raquel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455846/
https://www.ncbi.nlm.nih.gov/pubmed/26064054
http://dx.doi.org/10.2147/NDT.S65735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455846/
https://www.ncbi.nlm.nih.gov/pubmed/26064054
http://dx.doi.org/10.2147/NDT.S65735

Ejemplares similares